GSK plans orlistat to be first pan-European OTC switch

摘要

GlaxoSmithKline is to try to get the anti-obesity drug orlistat listed as a nonprescription medicine throughout the EU.A spokeswoman told The Journal this week that the company expects to apply to the European Medicines Agency by the end of the year for the product to be switched from prescription classification through the European centralised procedure.This will be the first time that the centralised system has been used for a prescription to nonprescription switch.If successful,GSK will be able to market the product in all EU countries without seeking separate national approvals.